Valtrax Research is opening — leave your email and we'll ping you the moment the first compounds are listed.
Every lot tested by Janoshik Analytical
Cart
Your cart is empty
Find
Valtrax Research is opening — leave your email and we'll ping you the moment the first compounds are listed.
Your cart is empty
Short-acting GHRH analogue · no DAC
A 29-residue GHRH(1-29) analogue without the Drug Affinity Complex, giving a short pulsatile profile. Supplied as a lyophilized powder for research purposes only.
Catalog opens shortly. Leave your address and we will ping you the moment this compound is orderable.
Tested lot by lot at ≥99% purity. The Janoshik certificate for your lot is emailed with the order.
Everything Valtrax Research ships is bench material for in-vitro work. None of it is a drug, a supplement, a cosmetic, or a medical device, and none of it is intended for human or animal use, ingestion, or administration. Placing an order is your confirmation that you are a qualified researcher buying for lawful research, under every Canadian law and regulation that applies to you.
A 29-residue GHRH(1-29) analogue, stabilized at four positions so it outlasts native GHRH — but without the Drug Affinity Complex that lets the DAC version bind serum albumin. Drop that albumin tether and the peptide clears fast, giving a sharp, short-lived pulse at the GHRH receptor.
That pulsatile profile is why researchers reach for the No-DAC form specifically: it tracks the natural rhythm of GHRH release more closely than a long-acting variant, which suits models built around how the pituitary answers brief, repeated signals.
The peptide is used to drive GHRH-receptor signaling on a short clock. Studies track receptor binding, the resulting GH and IGF-1 output, and how the No-DAC pulse compares against longer-acting analogues in the same hypothalamic–pituitary preparations.
Functionally this is GHRH chemistry made durable but not persistent. The peptide binds the GHRH receptor on pituitary somatotrophs and prompts growth-hormone release; stripping the DAC keeps each engagement brief, so the readout is a pulse rather than a plateau.
Research uses it to probe the GHRH-receptor end of the hypothalamic–pituitary axis — receptor binding, downstream GH and IGF-1 signaling, and how the timing of the stimulus shapes the response.
CJC-1295 came out of work on tetrasubstituted GHRH(1-29) analogues built to resist the enzymes that normally degrade the native hormone in minutes. Two forms diverged from that effort: one carrying the Drug Affinity Complex for albumin binding and extended action, and this No-DAC form that keeps the stabilizing substitutions but lets clearance stay quick.
Having both let researchers compare a long plateau against a short pulse using nearly the same backbone.
Teichman, S.L. et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of growth hormone–releasing hormone, in healthy adults.
PubMedIndependent testing lot by lot: identity, purity, net content. The certificate arrives by email with your order.
Janoshik Analytical, a laboratory Valtrax does not own, runs the testing — identity by mass spectrometry, purity by RP-HPLC at ≥99%. The certificate covering the lot you receive is also emailed with your order.
Same Shelf
